COVAMINF – The Working Group on COVID, Amyloid and Inflammation

CovAmInf is an international workgroup funded by the EU Joint Programme on Neurodegenerative Disease research (JPND) with the purpose of studying infection with the novel coronavirus SARS-COV-2 in context together with amyloid diseases such as Alzheimer’s, and also in context with inflammation, particularly in relation to chronic inflammation as driven by environmental pollution or as part of conditions such as obesity, diabetes, or autoimmune disease.

The CovAmInf workgroup exists not only to discuss science but to shape science priorities and public policy, therefore opinions and evidence from both inside and outside the laboratory or clinic are sought and valued.

Covid, Amyloid and Inflammation: why these three together?

Bidirectional feedbacks are either known, or else suggested by recent evidence, for each pair of entities out of inflammation, amyloid and SARS-COV-2.

Neuroinflammation accompanies most forms of cerebral amyloid disease, and may precede other symptoms. Sufferers from amyloid disease have highly elevated rates of fatality from SARS-COV-2, and sufferers from SARS-COV-2 infection are prone to suffer cerebral inflammation amongst other symptoms. CC licenced images: Covid virus image by Alexey Solodovnikov and Valeria Arkhipova. Skull by Steaphan Greene.

Can I join the discussion?

Please! The purpose of the COVAMINF workgroup is to build scientific and policy understanding both from and for the world.